Dose dependence of efficacy and safety of subcutaneous immunotherapy

Monaldi Archives for Chest Disease - Pulmonary Series

Volumn 65, Issue 1, 2006, Pages 41-43

  Incorvaia, Cristoforo ^a,e   Frati, F ^b,c   Puccinelli, P ^c   Riario Sforza, G G ^a   Dal Bo, S ^d  

^a PARKINSON INSTITUTE   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Scientific Department   (Italy)

^d Private Practice   (Italy)

^e NONE   (Italy)

Author keywords

Allergens; Atopy; Subcutaneous immunotherapy

Indexed keywords

ALLERGEN; GRASS POLLEN EXTRACT; HOUSE DUST ALLERGEN; HYMENOPTERA VENOM;

BIRCH; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; DERMATOPHAGOIDES; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; EXPOSURE; GRASS; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; MAINTENANCE DRUG DOSE; MAINTENANCE THERAPY; OPTIMAL DRUG DOSE; PARIETARIA; POLLEN; RAGWEED; REVIEW; RISK BENEFIT ANALYSIS;

EID: 33646404911     PISSN: 11220643     EISSN: 2465101X     Source Type: Journal    
DOI: 10.4081/monaldi.2006.585     Document Type: Review

References (31)

1. Bousquet J, Lockey R, Malling HJ (eds). WHO Position Paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. Allergy 1998; 53 (suppl. 54).
2. Bousquet J, van Cauwenberge P (eds). Allergic Rhinitis and its Impact on Asthma (ARIA). Position Paper endorsed by WHO. J Allergy Clin Immunol 2001; 108 (suppl 5): 147-334.
3. Johnstone DE. Study on the role of antigen dosage in the treatment of pollenosis and pollen asthma. AMA J Dis Child 1957; 94: 1-5.
4. Van Metre TE, Adkinson NF. Immunotherapy for aeroallergen disease. In Middleton E, Reed CE, Ellis EF, Adkinson NF Jr, Yunginger JW, Busse WW (eds): Allergy. Principles and practice. St. Louis, Mosby-Year Book, 1993: 1489-1509.
5. Golden DBK, Kagey-Sobotka A, Valentine NM, Lichtenstein LM. Dose dependence of hymenoptera venom immunotherapy. J Allergy Clin Immunol 1981; 67: 370-74.
6. Romagnani S. Immunologic influences on allergy and the TH1/TH2 balance. J Allergy Clin Immunol 2004; 113: 395-400.
7. Hosken NA, Shibuya K, Heath AW, Murphy KM, O'-Garra A. The effect of antigen dose on CD4+ T helper cells phenotype development in a T cell receptor-alpha beta-transgenic model. J Exp Med 1995; 182: 1579-84.
8. Secrist H, DeKruyff RH, Umetsu DT. Interleukin 4 production by CD4+ T cells from allergic individuals is modulated by antigen concentration and antigen-presenting cell type. J Exp Med 1995; 181: 1081-9.
9. Strid J, Thomson M, Hourihane J, Kimber I, Strobel S. A novel model of sensitization and oral tolerance to peanut protein. Immunology 2004; 113: 293-303.
10. Noirey N, Rougier N, André C, Schmitt D, Vincent C. Langerhans-like dendritic cells generated from cord blood progenitors internalize pollen allergens by macropinocytosis, and part of the molecules are processed and can activate autologous naive T lymphocytes. J Allergy Clin Immunol 2000; 105: 1194-201.
11. Ronmark E, Jonsson E, Platts-Mills T, et al. Incidence and remission of asthma in schoolchildren: report from the obstructive lung disease in northern Sweden studies. Pediatr 2001; 107: 37-41.
12. Bousquet J, Ménardo JL, Aznar R, Robinet-Lévy M, Michel FB. Clinical and immunological survey in beekepers in relation to their sensitization. J Allergy Clin Immunol 1984; 73: 332-40.
13. Turkeltaub PC. The importance of allergen dose on the safety and efficacy of immunotherapy of ragweed hay fever with standardized short ragweed extract. J Allergy Clin Immunol 1986; 77 (part 2): 211.
14. Osterballe O. Immunotherapy in hay fever with two major allergens 19, 25 and partially purified extract of timothy grass pollen. A controlled double blind study. In vivo variables, season I. Allergy 1980; 35: 473-89.
15. Van Metre TE, Adkinson NF Jr, Lichtenstein ML, et al. A controlled study on the effectiveness of the Rinkel method of immunotherapy for ragweed pollen hay fever. J Allergy Clin Immunol 1980; 65: 288-97.
16. Van Metre TE, Adkinson NF Jr, Amodio FJ, et al. A comparison of immunotherapy schedules for injection treatment of ragweed pollen hay fever. J Allergy Clin Immunol 1982; 69: 181-93.
17. Creticos PS, Van Metre TE, Mardiney MR, Rosenberg GL, Norman PS, Adkinson NF Jr. Dose response of IgE and IgG antibodies during ragweed immunotherapy. J Allergy Clin Immunol 1984; 73: 94-104.
18. Creticos PS, Reed CE, Norman PS, et al. Ragweed immunotherapy in adult asthma. N Engl J Med 1996; 334: 501-6.
19. Bodtger U, Poulsen LK, Jacobi HH, Malling HJ. The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study. Allergy 2002; 57: 297-305.
20. Ortolani C, Pastorello E, Incorvaia C, et al. A double-blind, placebo-controlled study of immunotherapy with an alginate-conjugated extract of Parietaria judaica in patients with Parietaria hay fever. Allergy 1994; 49: 13-21.
21. Bousquet J, Calvayrac P. Guerin B, et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. I. In vivo and in vitro parameter after a short course of treatment. J Allergy Clin Immunol 1985; 76: 734-44.
22. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993; 91: 709-722.
23. Wahn U, Schweter C, Lind P, Lowenstein H. Prospective study on immunologic changes induced by two different Dermatophagoides pteronyssinus extracts prepared from whole mite culture and mite bodies. J Allergy Clin Immunol 1988; 82: 360-70.
24. Taylor WW, Ohman J jr, Lowell FC. Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of bronchial responses to cat allergen and histamine. J Allergy Clin Immunol 1978; 61: 283-7.
25. Ohman J Jr, Findlay SR, Leiterman KM. Immunotherapy in cat-induced asthma. Double-blind trial with evaluation of in vivo and in vitro responses. J Allergy Clin Immunol 1984; 74: 230-9.
26. Sundin B, Lilja G, Graff-Lonnevig V, et al. Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. J Allergy Clin Immunol 1986; 77: 478-87.
27. Alvarez-Cuesta E, Cuesta-Herranz J, Puyana-Ruiz J, Cuesta-Herranz C, Blanco-Quiros A. Monoclonal antibody-standardized cat extract immunotherapy: risk-benefit effects from a double-blind placebo-controlled study. J Allergy Clin Immunol 1994; 93: 556-66.
28. Nanda A, O'Connor M, Anand M, et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol 2004; 114: 1339-44.
29. Rueff F, Wenderoth A, Przybilla B. Patients still reacting to a sting challenge while receiving conventional Hymenoptera venom immunotherapy are protected by increased venom doses. J Allergy Clin Immunol 2001; 108: 1027-32.
30. Hunt KJ, Valentine NM, Sobotka AK, Benton AW, Amodio FJ, Lichtenstein LM. A controlled trial of immunotherapy in insect hypersensitivity. N Engl J Med 1978; 299: 157-61.
31. Muller U, Thurneer U, Patrizzi R, Spiess J, Hoignè R. Immunotherapy in bee sting hypersensitivity. Bee venom versus whole-body extract. Allergy 1979; 34: 369-78.